Heron Therapeutics (HRTX)

$

9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
.
9
8
7
6
5
4
3
2
1
0
0
$0.01 (-0.57%)Past DayToday's Volume:
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
,
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
,
9
8
7
6
5
4
3
2
1
0
0

About

Business overview of Heron Therapeutics (HRTX)
Heron Therapeutics Inc is a commercial-stage biotechnology company. It is focused on improving the lives of patients by developing treatments that address some of the unmet patient needs. The company's product portfolio consists of APONVIE, SUSTOL, ZYNRELEF, and CINVANTI.

Key Insights

Critical company metrics and information

  • Share Price

    $1.77

  • Market Cap

    $269.21 Million

  • Total Outstanding Shares

    152.10 Million Shares

  • Total Employees

    126

  • Dividend

    No dividend

  • IPO Date

    August 27, 1987

  • SIC Description

    Pharmaceutical Preparations

  • Homepage

    https://www.herontx.com

Historical Stock Splits

Execution DateSplit Amount
No Historical Stock Splits

Cash Flow Statement

October 1, 2023 to September 30, 2024
MetricValue
Net Cash Flow From Investing Activities, Continuing$-1.54 Million
Net Cash Flow$-9.12 Million
Net Cash Flow From Operating Activities, Continuing$-8.29 Million
Net Cash Flow From Investing Activities$-1.54 Million
Net Cash Flow From Operating Activities$-8.29 Million
Net Cash Flow From Financing Activities, Continuing$716,000.00
Net Cash Flow, Continuing$-9.12 Million
Net Cash Flow From Financing Activities$716,000.00

Income Statement

October 1, 2023 to September 30, 2024
MetricValue
Cost Of Revenue$38.30 Million
Revenues$137.74 Million
Net Income/Loss Attributable To Noncontrolling Interest$0.00
Net Income/Loss Available To Common Stockholders, Basic$-27.97 Million
Gross Profit$99.43 Million
Costs And Expenses$125.35 Million
Preferred Stock Dividends And Other Adjustments$0.00
Basic Earnings Per Share$-0.16
Other Operating Expenses$87.28 Million
Net Income/Loss$-27.97 Million
Participating Securities, Distributed And Undistributed Earnings/Loss, Basic$0.00
Benefits Costs and Expenses$125.35 Million
Operating Income/Loss$-25.92 Million
Diluted Earnings Per Share$-0.16
Net Income/Loss Attributable To Parent$-27.97 Million
Diluted Average Shares$156.60 Million
Income/Loss From Continuing Operations Before Tax$12.38 Million
Research and Development$38.07 Million
Income/Loss From Continuing Operations After Tax$-27.97 Million
Basic Average Shares$156.60 Million
Operating Expenses$125.35 Million

Balance Sheet

October 1, 2023 to September 30, 2024
MetricValue
Liabilities$260.78 Million
Other Non-current Assets$10.18 Million
Other Current Liabilities$66.83 Million
Noncurrent Assets$25.59 Million
Equity Attributable To Parent$-40.01 Million
Inventory$45.95 Million
Equity$-40.01 Million
Current Liabilities$85.54 Million
Liabilities And Equity$220.78 Million
Fixed Assets$15.41 Million
Noncurrent Liabilities$175.24 Million
Current Assets$195.19 Million
Assets$220.78 Million
Accounts Payable$10.19 Million
Cash$70.90 Million
Equity Attributable To Noncontrolling Interest$0.00
Other Current Assets$78.34 Million
Wages$8.53 Million

Historical Dividends

Announcement DatePayment DateRecord DateAmountFrequency
No historical dividends
Boost your savings and earn 4.35% APY with a Marcus by Goldman Sachs savings account, a rate that's 8x the national averagewhen signing up with Financhle. No fees, no minimum deposits, backed by the financial expertise of Goldman Sachs. Terms apply.
Earnings CalendarNews ArticlesAbout UsPrivacy & Cookies Info

â“’ 2024 Financhle. All Rights Reserved.